$LYEL (LYELL IMMUNOPHARMA) — 8-K: LYL273 manufacturing transfer complete; Phase 1/2 data and FDA End-of-Phase 1 meeting now expected in 2027

Lyell Immunopharma completed the planned technology transfer for LYL273 to its LyFE Manufacturing Center in Bothell, Washington, following FDA review of an improved manufacturing process and updated analytical methods. The Phase 1/2 trial in relapsed/refractory metastatic colorectal cancer continues enrolling patients to determine the recommended Phase 2 dose and optimized safety management plan. Additional clinical data and the planned End-of-Phase 1 meeting with the FDA are now expected in 2027.

Lyell Immunopharma completed the planned technology transfer for LYL273 to its LyFE Manufacturing Center in Bothell, Washington, following FDA review of an improved manufacturing process and updated a